Lack of clinically significant pharmacokinetic interaction between the thrombopoietin receptor agonist eltrombopag and hepatitis C virus protease inhibitors boceprevir and telaprevir.

@article{Wire2014LackOC,
  title={Lack of clinically significant pharmacokinetic interaction between the thrombopoietin receptor agonist eltrombopag and hepatitis C virus protease inhibitors boceprevir and telaprevir.},
  author={Mary Beth Wire and Lei Fang and A. Makun Hussaini and Joseph F. Kleha and Dickens Theodore},
  journal={Antimicrobial agents and chemotherapy},
  year={2014},
  volume={58 11},
  pages={6704-9}
}
Eltrombopag is an orally bioavailable thrombopoietin receptor agonist approved for the treatment of thrombocytopenia associated with chronic immune (idiopathic) thrombocytopenic purpura and chronic hepatitis C virus (HCV) infection. This study evaluated the potential drug-drug interactions between eltrombopag and the HCV protease inhibitors boceprevir and… CONTINUE READING